Gyre Therapeutics, Inc. (GYRE)
(Delayed Data from NSDQ)
$7.20 USD
+0.18 (2.56%)
Updated Aug 7, 2025 04:00 PM ET
After-Market: $7.20 0.00 (0.00%) 6:18 PM ET
4-Sell of 5 4
D Value F Growth B Momentum F VGM
Fundamental Charts
About Dividend Yield (TTM)
Gyre Therapeutics, Inc.'s dividend yield currently sits at 0%, which is in-line with the Medical - Biomedical and Genetics industry's yield of 0.00%.
The company's trailing twelve month (TTM) Dividend Yield calculates the indicated annual dividend divided by the stock price. This value is always expressed as a percentage. This is the return on investment that is specifically attributed to the expected dividends that are paid out over a year. Note: investors should not base their investments on the size of the dividend yield alone. Seek attractive dividend yields, but only on top rated stocks with a solid payment history.
GYRE 7.20 +0.18(2.56%)
Will GYRE be a Portfolio Killer in August?
Zacks Investment Research is releasing its prediction for GYRE based on the 1-3 month trading system that more than doubles the S&P 500.
Zacks News for GYRE
Arcellx, Inc. (ACLX) Reports Q2 Loss, Misses Revenue Estimates
Prothena (PRTA) Reports Q2 Loss, Lags Revenue Estimates
GYRE: What are Zacks experts saying now?
Zacks Private Portfolio Services
Clene Inc. (CLNN) Reports Q1 Loss, Lags Revenue Estimates
Blueprint Medicines (BPMC) Reports Q1 Loss, Lags Revenue Estimates
Other News for GYRE
Gyre Therapeutics: Unique Business Model, Unique Challenges
Stifel Nicolaus Initiates a Buy Rating on Gyre Therapeutics (GYRE)
Innovative Strategy and Strong Pipeline Position Gyre Therapeutics for Market Success
Gyre Therapeutics (GYRE) Begins Phase 1 Trial for Pulmonary Hypertension Drug | GYRE Stock News
Gyre Therapeutics Announces First Dosing in Phase 1 Trial of F230 for Pulmonary Arterial ...